Last reviewed · How we verify
NCT05943288: EuroCADe
Safety and Efficacy of the Olympus CADe System in Real-time Colonoscopy
trial testing OIP-1 in Colorectal Cancer in 850 participants. Completed in 31 July 2024.
31 July 2024
Quick facts
| Lead sponsor | Olympus Europe SE & Co. KG |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 850 |
| Start date | 25 April 2023 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 6 locations across Belgium, Sweden, Germany, Spain |
Drugs / interventions tested
- OIP-1
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Olympus Europe SE & Co. KG — full company profile →
Who can join
Adults 45 to 80, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicenter, randomized Trial to assess the safety and efficacy of the Olympus Endoscopy Computer-Aided Detection (CADe) system, OIP-1, in the detection of colorectal neoplasia's during real-time colonoscopy. The aim of this system is to improve physician performance in the detection of potential mucosal abnormalities during colonoscopy performed for primary Colorectal Cancer screening or postpolypectomy surveillance.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05943288
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Olympus Europe SE & Co. KG trials
Trials by the same sponsor.
- NCT07253727 — The LUCENT Study - LUng Lesion Assessment Via BF-UCP190F for Central and Extended Nodal Targeting · not yet recruiting
- NCT05869838 — A Clinical Study on Endoscopic and Histopathological Outcomes of Screening and Surveillance Colonoscopies · completed
- NCT05129449 — A Clinical Study With the Medical Device PowerSpiral for Endoscopic Retrograde Cholangio-Pancreatography (ERCP) · completed
- NCT03955081 — A Clinical Study With the Medical Device PowerSpiral for Deep Enteroscopy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05943288 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Olympus Europe SE & Co. KG
- Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05943288.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing